2022
Feasibility and Sensitivity of Saliva GeneXpert MTB/RIF Ultra for Tuberculosis Diagnosis in Adults in Uganda
Byanyima P, Kaswabuli S, Musisi E, Nabakiibi C, Zawedde J, Sanyu I, Sessolo A, Andama A, Worodria W, Huang L, Davis JL. Feasibility and Sensitivity of Saliva GeneXpert MTB/RIF Ultra for Tuberculosis Diagnosis in Adults in Uganda. Microbiology Spectrum 2022, 10: e00860-22. PMID: 36154664, PMCID: PMC9603304, DOI: 10.1128/spectrum.00860-22.Peer-Reviewed Original ResearchMeSH KeywordsAdultFeasibility StudiesHIV InfectionsHumansMycobacterium tuberculosisRifampinSalivaSensitivity and SpecificityTuberculosis, Lymph NodeUgandaConceptsGeneXpert MTB/RIF UltraMTB/RIF UltraXpert UltraTB diagnosisMolecular testingHigh TB burden settingsCulture-confirmed TB casesSaliva samplesTB diagnostic evaluationActive tuberculosis diseaseProspective observational studyActive TB diagnosisCause of morbidityAcid-fast bacilliComposite reference standardReference standardCase-only studySingle saliva sampleWorld Health OrganizationSpot sputumTB evaluationConsecutive adultsTB casesBurden settingsOutpatient department
2018
Association of Rapid Molecular Testing With Duration of Respiratory Isolation for Patients With Possible Tuberculosis in a US Hospital
Chaisson LH, Duong D, Cattamanchi A, Roemer M, Handley MA, Schillinger D, Sur M, Pham P, Lin MA, Goldman LE, Quan J, Perez S, Healy M, Higashi J, Winston L, Haller B, Luetkemeyer AF, Davis JL. Association of Rapid Molecular Testing With Duration of Respiratory Isolation for Patients With Possible Tuberculosis in a US Hospital. JAMA Internal Medicine 2018, 178: 1380-1388. PMID: 30178007, PMCID: PMC6368387, DOI: 10.1001/jamainternmed.2018.3638.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAlgorithmsFemaleHumansInfection ControlMaleMiddle AgedMycobacterium tuberculosisPatient IsolationProspective StudiesSensitivity and SpecificityTuberculosisUnited StatesConceptsDiscontinuation of isolationMolecular testing algorithmRespiratory isolationMolecular testingPossible tuberculosisActive tuberculosisPreimplementation periodUS hospitalsZuckerberg San Francisco General HospitalSan Francisco General HospitalGeneXpert MTB/RIFCulture-confirmed tuberculosisPatient-centered evaluationActive pulmonary tuberculosisProportion of patientsProspective cohort studyLength of stayMTB/RIFRapid test resultsRapid molecular testingSputum smear microscopyMolecular testing strategiesHealth care settingsCulture-negative resultsTB-negative patients
2015
Transcriptional Adaptation of Drug-tolerant Mycobacterium tuberculosis During Treatment of Human Tuberculosis
Walter ND, Dolganov GM, Garcia BJ, Worodria W, Andama A, Musisi E, Ayakaka I, Van TT, Voskuil MI, de Jong BC, Davidson RM, Fingerlin TE, Kechris K, Palmer C, Nahid P, Daley CL, Geraci M, Huang L, Cattamanchi A, Strong M, Schoolnik GK, Davis JL. Transcriptional Adaptation of Drug-tolerant Mycobacterium tuberculosis During Treatment of Human Tuberculosis. The Journal Of Infectious Diseases 2015, 212: 990-998. PMID: 25762787, PMCID: PMC4548467, DOI: 10.1093/infdis/jiv149.Peer-Reviewed Original ResearchConceptsDrug-tolerant bacilliDrug exposureDrug-susceptible pulmonary tuberculosisDrug-tolerant Mycobacterium tuberculosisDrug-susceptible Mycobacterium tuberculosisMycobacterium tuberculosisTuberculosis treatment regimensInitial drug exposureReverse transcription-polymerase chain reactionMessenger RNA expressionM. tuberculosis gene expressionDrug efflux pumpsSerial sputaPulmonary tuberculosisTreatment initiationNovel drug targetsTreatment regimensPolymerase chain reactionToxin-antitoxin genesHuman tuberculosisRate of declineDrug responsivenessStress signatureMarked downregulationDrug tolerance